Skip to main content
    A

    AbbVie Inc (ABBV)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $286.82
    +1.19 (+0.41%)

    Market Cap: $504.76B

    Last updated: Oct 27, 2026 at 10:41 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(35/39)
    Avg Surprise
    +2.23%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$3.78
    Range$3.61 - $3.86
    21 analysts
    EPS RevisionsNo revisions (7d)
    0
    8
    30d
    EPS Estimate DriftChange to current
    90d ago$3.85-1.7%
    60d ago$3.84-1.7%
    30d ago$3.84-1.7%
    7d ago$3.79-0.2%
    Current$3.78
    Revenue Consensus
    $17.3B
    Range$17.2B - $17.6B
    20 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.90
    Range$3.76 - $4.20
    27 analysts
    Revenue Consensus
    $18.8B
    Range$18.4B - $19.2B
    24 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.90---
    Sep 26EST
    		-$3.78---
    Jun 26
    Reported Jul 31
    		$3.65$3.64+0.27%Beat+22.9%
    Mar 26
    Reported Apr 29
    		$2.65$2.67-0.75%Miss+7.7%
    Dec 25
    Reported Feb 4
    		$2.71$2.65+2.26%Beat+25.5%
    Sep 25
    Reported Oct 31
    		$1.86$1.78+4.49%Beat-38.0%
    Jun 25
    Reported Jul 31
    		$2.97$2.91+2.06%Beat+12.1%
    Mar 25
    Reported Apr 25
    		$2.46$2.40+2.50%Beat+6.5%
    Dec 24
    Reported Jan 31
    		$2.16$2.12+1.89%Beat-22.6%
    Sep 24
    Reported Oct 30
    		$3.00$2.92+2.74%Beat+1.7%
    Jun 24
    Reported Jul 25
    		$2.65$2.66-0.38%Miss-8.9%
    Mar 24
    Reported Apr 26
    		$2.31$2.23+3.59%Beat-6.1%
    Dec 23
    Reported Feb 2
    		$2.79$2.77+0.72%Beat-22.5%
    Sep 23
    Reported Oct 27
    		$2.95$2.87+2.79%Beat-19.4%
    Jun 23
    Reported Jul 27
    		$2.91$2.81+3.56%Beat-13.6%
    Mar 23
    Reported Apr 27
    		$2.46$2.49-1.20%Miss-22.2%
    Dec 22
    Reported Feb 9
    		$3.60$3.58+0.56%Beat+8.8%
    Sep 22
    Reported Oct 28
    		$3.66$3.57+2.52%Beat+9.9%
    Jun 22
    Reported Jul 29
    		$3.37$3.31+1.81%Beat+8.4%
    Mar 22
    Reported Apr 29
    		$3.16$3.14+0.64%Beat+7.1%
    Dec 21
    Reported Feb 2
    		$3.31$3.28+0.91%Beat+13.4%
    Sep 21
    Reported Oct 29
    		$3.33$3.22+3.42%Beat+17.7%
    Jun 21
    Reported Jul 30
    		$3.11$3.03+2.64%Beat+32.9%
    Mar 21
    Reported Apr 30
    		$2.95$2.83+4.24%Beat+21.9%
    Dec 20
    Reported Feb 3
    		$2.92$2.85+2.46%Beat+32.1%
    Sep 20
    Reported Oct 30
    		$2.83$2.77+2.17%Beat+21.5%
    Jun 20
    Reported Jul 31
    		$2.34$2.20+6.36%Beat+3.5%
    Mar 20
    Reported May 1
    		$2.42$2.25+7.56%Beat+13.1%
    Dec 19
    Reported Feb 7
    		$2.21$2.19+0.91%Beat+16.3%
    Sep 19
    Reported Nov 1
    		$2.33$2.30+1.30%Beat+8.9%
    Jun 19
    Reported Jul 26
    		$2.26$2.21+2.26%Beat+13.0%
    Mar 19
    Reported Apr 25
    		$2.14$2.07+3.38%Beat+14.4%
    Dec 18
    Reported Jan 25
    		$1.90$1.93-1.55%Miss+28.4%
    Sep 18
    Reported Nov 2
    		$2.14$2.00+7.00%Beat+51.8%
    Jun 18
    Reported Jul 27
    		$2.00$1.97+1.52%Beat+40.8%
    Mar 18
    Reported Apr 26
    		$1.87$1.79+4.47%Beat+46.1%
    Dec 17
    Reported Jan 26
    		$1.48$1.43+3.50%Beat+23.3%
    Sep 17
    Reported Oct 27
    		$1.41$1.39+1.44%Beat-
    Jun 17
    Reported Jul 28
    		$1.42$1.40+1.43%Beat-
    Mar 17
    Reported Apr 27
    		$1.28$1.26+1.59%Beat-
    Dec 16
    Reported Jan 27
    		$1.20$1.20+0.00%Beat-

    Dividends

    Dividend Metrics

    Forward Yield2.41%
    Forward Annual Dividend$6.92
    Payout Ratio62.75%
    FrequencyQuarterly
    Pay MonthsFeb, May, Aug, Nov

    Growth

    3Y CAGR+5.17%
    5Y CAGR+6.81%
    ABBV dividend history and ex-dividend datesRun ABBV in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio26.39EV/EBITDA29.75x
    Price/FCF27.86xFCF Yield3.59%
    Profitability
    Profit Margin9.80%Operating Margin40.00%
    ROE62.30%ROIC12.69%
    Financial Health
    Debt/Equity-11.93xInterest CoverageN/A
    Current Ratio0.81xQuick Ratio0.69x
    Trading Statistics
    Beta0.23Avg Volume5.26M
    52-Week High$291.4052-Week Low$188.25

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$283.75
    SMA 20$275.13
    SMA 50$265.53
    SMA 200$233.36
    EMA 10$282.93
    EMA 20$277.45
    EMA 50$266.92
    EMA 200$239.94

    MACD

    Line: 6.91Signal: 6.26Hist: 0.65

    ADX

    ADX: 34.3+DI: 26.4-DI: 12.2

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down36.0
    PSAR$290.87

    Bollinger Bands

    Upper Band$296.11
    Lower Band$254.15
    %B Position1525%(Upper)
    Band Width0.78

    RSI (14-Day)

    Neutral
    67.2

    Momentum Oscillators

    Stoch %K81.2
    Stoch %D82.1
    Williams %R-17.8
    ROC (10d)2.7%
    Momentum7.41
    CCI (20d)86.7
    MFI (14d)57.3

    Volatility Measures

    ATR (14d)$6.53(2.3%)
    StdDev (20d)10.49
    Hist Vol21.8%(Moderate)

    Volume Flow

    VWAP$287.20
    OBV154.3M
    AD Line-4.4B
    CMF (20d)-0.189

    Volume Metrics

    Avg Vol (20d)5.3M
    Vol Ratio0.8x
    VWMA (20d)$275.34

    Pivot Points

    R3$291.97
    R2$289.37
    R1$287.50
    Pivot Point$284.90
    S1$283.04
    S2$280.44
    S3$278.57

    Advanced Oscillators

    TSI34.49
    Ultimate Osc53.3
    KST82.90

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$16.99B$15.00B$16.62B$15.78B$15.42B$13.34B$15.10B$14.46B$14.46B$12.31B$14.30B$13.93B
    Cost of Revenue$4.58B$4.96B$6.64B$7.98B$5.17B$4.00B$4.15B$4.29B$4.20B$4.26B$5.49B$6.55B
    Gross Profit$12.41B$10.04B$9.98B$7.79B$10.25B$9.34B$10.95B$10.17B$10.26B$8.05B$8.81B$7.38B
    Operating Expenses$5.98B$6.05B$5.43B$5.89B$5.36B$5.61B$12.44B$6.33B$6.26B$5.25B$5.62B$5.09B
    R&D$2.34B$2.47B$2.58B$2.32B$2.13B$2.07B$6.77B$2.13B$1.95B$1.94B$1.93B$1.72B
    SG&A$3.63B$3.58B$3.07B$3.57B$3.25B$3.54B$5.67B$4.21B$4.31B$3.31B$3.69B$3.37B
    Operating Income$6.43B$3.99B$4.54B$1.90B$4.89B$3.73B$-1,490,000,000$3.83B$4.00B$2.80B$3.19B$2.28B
    Interest Income$-679,000,000$-645,000,000$-655,000,000$-667,000,000$-678,000,000$-627,000,000$-610,000,000$-591,000,000$-506,000,000$-453,000,000$-378,000,000$-398,000,000
    Interest Expense$2.15B$2.95B$1.88B$1.19B$3.34B$2.07B$779.00M$1.75B$1.85B$1.04B$1.98B$328.00M
    Income Before Tax$4.28B$1.04B$2.67B$714.00M$1.55B$1.66B$-2,269,000,000$2.08B$2.15B$1.75B$1.21B$1.95B
    Income Tax Expense$662.00M$342.00M$853.00M$526.00M$613.00M$372.00M$-2,246,000,000$520.00M$773.00M$383.00M$388.00M$172.00M
    Net Income$3.62B$697.00M$1.81B$188.00M$941.00M$1.29B$-23,000,000$1.56B$1.37B$1.37B$824.00M$1.78B
    EBITDA$6.84B$3.62B$5.31B$3.44B$4.28B$4.33B$443.00M$4.75B$4.78B$4.28B$3.67B$4.59B
    EBIT$4.96B$1.68B$3.32B$1.38B$2.23B$2.29B$-1,659,000,000$2.67B$2.65B$2.21B$1.59B$2.35B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    Starting Over: The 15-Stock Dividend Portfolio My Own Rules Would Build

    TOLL+M disciplined 15-stock build: 15 holdings, average forward yield >=3%, one name per sleeve, no manager overrides Toll-road core via EPD and WMB - EPD yields ~6%, 27-year increase streak, DCF coverage >1.6x; WMB grows faster but has a 2016 cut scar Real-asset income engines...

    Leo Nelissen
    •
    7/6/26
    •
    492
    Portfolio Construction, Model Portfolio, Dividend Investing, Dividend Growth
    Also mentions:
    LBTPLEPDWMBUNP

    The Intelligent Compounder's Playbook: Five Dividend Aristocrats Built to Outlast the Next Downturn

    Five dividend aristocrats stress-tested across 170+ quality metrics, ranked by conviction GNG Safety Scores span from 70.47 to a perfect 100 across the final five picks One insurer just posted record combined ratios and landed a $20B government contract The "cheapest" candidate on the screen carried...

    Glenn Ford
    •
    3/18/26
    •
    401
    dividend aristocrats
    Also mentions:
    JNJPGPEPSJMABBV

    Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover

    Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22...

    Glenn Ford
    •
    2/12/26
    •
    178
    Income Investing, value investing
    Also mentions:
    MRKBMYGILDABBV

    The Income Fortress: Building a 3.5% Yield Without the Usual Landmines

    3.5% yield with 68% avg payout ratio vs typical high-yield portfolios at 95%+ - sustainability over maximum income Systematic filtering: 6,000 stocks → 27 survivors through 5-pillar scoring (Income, Safety, Growth, Risk, Valuation) Growth ballast strategy...

    Glenn Ford
    •
    12/16/25
    •
    506
    Income Investing, Dividend Investing, growth-stocks
    Also mentions:
    MSFTCNQJPMRIOSNA

    Government Contracts

    Gov Obligations (TTM)
    $380232
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    164
    New Awards (TTM)
    162
    Avg Remaining Term
    N/A

    Top agency: Department of Defense at 98.6% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    SPE2D626F16R3Department of DefenseDefense Logistics Agency$23920Dec 12, 2025
    SPE2D626F7276Department of DefenseDefense Logistics Agency$20856Oct 30, 2025
    36C24225P1435Department of Veterans AffairsDepartment of Veterans Affairs$15759Aug 28, 2025
    SPE2D626F42WRDepartment of DefenseDefense Logistics Agency$4635Feb 3, 2026
    SPE2D626F15QDDepartment of DefenseDefense Logistics Agency$4014Jan 20, 2026
    SPE2D625F2JARDepartment of DefenseDefense Logistics Agency$4014Sep 2, 2025
    SPE2D626F63G2Department of DefenseDefense Logistics Agency$3807Dec 8, 2025
    SPE2D626F2X20Department of DefenseDefense Logistics Agency$3440Mar 5, 2026
    SPE2D626F79T2Department of DefenseDefense Logistics Agency$3300Dec 19, 2025
    SPE2D626F50L8Department of DefenseDefense Logistics Agency$3300Dec 11, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    AbbVie Submits Biologics License Application for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma

    AbbVie has submitted a Biologics License Application (BLA) to the U.S. FDA for etentamig, a second-generation BCMA x CD3 bispecific antibody...

    Investing News Network•10/27/26•Neutral

    Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)

    Allergan Aesthetics, an AbbVie company, announced the 2026 grant recipients for "The Confidence Collective: Empowering Women Entrepreneurs," an initiative funded by BOTOX® Cosmetic. Each of the 20 women entrepreneurs...

    AbbVie News Center•10/27/26•Bullish

    Rare Disease Pharmaceutical Service Market Report Examines Industry Trends, Growth Drivers And Future Outlook

    The rare disease pharmaceutical service market is experiencing rapid growth, projected to reach $150.96 billion in 2026 with a 13.2% CAGR...

    openPR.com•10/27/26•Somewhat-Bullish

    Should You Invest in the State Street Health Care Select Sector SPDR ETF ETF (XLV)?

    This article evaluates the State Street Health Care Select Sector SPDR ETF (XLV), highlighting its suitability for investors seeking broad exposure to the Healthcare sector. Launched in 1998...

    Yahoo! Finance Canada•10/26/26•Somewhat-Bullish

    Kymera Therapeutics (KYMR) Could Be 17% Undervalued Following Its Earnings Preview

    Kymera Therapeutics (KYMR) is expected to post a loss of $1.26 per share with sharply higher revenue for the September 2026 quarter...

    Simply Wall Street•10/26/26•Neutral

    ABBV Valuation and Fair Value

    P/E
    26.4x
    Forward P/E
    16.2x
    EV/EBITDA
    29.8x
    P/FCF
    27.9x
    PEG
    0.5x
    P/B
    -85.5x
    See GNG's fair value

    ABBV Profitability: Margins, ROIC and FCF

    Gross margin
    62.5%
    Operating margin
    40.0%
    Net margin
    9.8%
    ROIC
    12.7%
    ROE
    62.3%
    FCF margin
    28.3%
    FCF yield
    3.6%

    ABBV Competitors

    CompanyTicker
    Johnson & JohnsonJNJ
    UnitedHealth Group IncorporatedUNH
    Eli Lilly and CompanyLLY
    Merck & Company IncMRK
    Novartis AG ADRNVS
    AstraZeneca PLCAZN
    Thermo Fisher Scientific IncTMO
    Amgen IncAMGN

    Sector: Healthcare

    ABBV Analyst Ratings

    Consensus
    Buy
    Analysts
    30
    Strong Buy
    8
    Buy
    16
    Hold
    5
    Sell
    0
    Strong Sell
    1

    ABBV Bull Case vs Bear Case

    Bull case

    • ABBV converts 28.3% of revenue into free cash flow.
    • ABBV beat EPS estimates in 87.5% of its last 8 reported quarters.
    • ABBV grew quarterly revenue 10.2% year over year.

    ABBV Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    1.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $3.78
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 8 down

    ABBV Dividend

    Forward yield
    2.4%
    Payout ratio
    62.8%
    3Y DPS growth
    5.2%
    5Y DPS growth
    6.8%
    Pay months
    Feb, May, Aug, Nov
    ABBV dividend history

    Frequently Asked Questions About ABBV

    What is ABBV's current dividend yield?

    AbbVie Inc (ABBV) has a forward dividend yield of 2.41%.

    Does ABBV pay dividends?

    Yes, AbbVie Inc pays dividends with a forward dividend yield of 2.41%.

    What is ABBV's P/E ratio?

    AbbVie Inc has a price-to-earnings (P/E) ratio of 26.39.

    What is ABBV's market cap?

    AbbVie Inc (ABBV) has a market capitalization of $504.76B with a current stock price of $286.82.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In